ArticleESMO real world data and digital oncology2026
Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although enzalutamide and darolutamide share a common mechanism of action targeting the androgen receptor pathway, they differ in their molecular structure and pharmacological properties, which may influence their efficacy and safety. However, real-world evidence directly comparing these agents in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) remains limited. Materials and methods: In this multicenter retrospective study, data from 198 patients who received enzalutamide or darolutamide as their first androgen receptor signaling inhibitor (ARSI) during treatment of nmCRPC were analyzed. Adverse events (AEs) and prostate-specific antigen (PSA) responses were compared. Progression of PSA and development of metastases were assessed using the Fine-Gray subdistribution hazards model, adjusting for death as a competing risk. Results: In the cohort, 94 (47%) patients received enzalutamide and 104 (53%) received darolutamide. Incidence rates of any-grade AEs and grade ≥3 AEs were similar between the two groups ( Conclusions: Enzalutamide and darolutamide had comparable safety and oncological outcomes in patients with nmCRPC. These findings support the use of either agent as an appropriate first ARSI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.